China NMPA Drug Inspection - Hubei Danao Pharmaceutical Co., Ltd. - Anluotong tablets

On November 24, 2017, the Henan Provincial Food and Drug Administration issued an announcement regarding three batches of substandard drugs, following tests conducted by provincial and municipal inspection institutes. The regulatory action involved products from three companies: Huixian Baiquan Traditional Chinese Medicine Pieces Co., Ltd., Shandong Zhencheng Zhiyuan Traditional Chinese Medicine Pieces Co., Ltd., and Hubei Meibao Pharmaceutical Co., Ltd. Huixian Baiquan's Epimedium (batch 161201) was found to have substandard content. Shandong Zhencheng Zhiyuan's Coltsfoot Flower (batch 16061901) and Hubei Meibao Pharmaceutical's Anluotong Tablets (batch 160506) both exhibited substandard appearance. These findings indicate non-compliance with established quality standards for pharmaceutical products under the regulatory oversight of China's National Medical Products Administration framework, as implemented by the provincial authority. In response, the Henan Provincial Food and Drug Administration mandated immediate risk control measures. These actions included sealing, seizing, and suspending sales of the affected drug batches. Additionally, relevant regulatory departments were instructed to conduct investigations and impose penalties on the involved companies as prescribed by law. This enforcement highlights the commitment to ensuring drug quality and patient safety within the Chinese pharmaceutical market.